Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Harold C. Neu Professor of Medicine
Chief, Division of Infectious Diseases
Columbia University Medical Center
New York, New York

Topics of Professional Interest:
  • Antiretroviral therapy
  • HIV drug resistance
  • HIV vaccines
Current Professional Summary:

Dr Hammer is Harold C. Neu Professor of Medicine and Chief of the Division of Infectious Diseases at the Columbia University Medical Center. He serves as an investigator in the NIAID sponsored AIDS Clinical Trials Group and HIV Vaccine Trials Network (HVTN).

Committees and Organizations:
Education:
  • Columbia College, BA
  • Columbia University College of Physicians and Surgeons, MD
  • Presbyterian Hospital and Stanford University Hospital, Medical Residency
  • Massachusetts General Hospital, Fellowship, Infectious Diseases
Selected Publications:
  1. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-Sponsored AIDS Clinical Trials Group Study 175. New Engl J Med. 1996;335:1081-1096.
  2. Hammer SM, Squires KE, Hughes MD, et al (for the AIDS Clinical Trials Group 320 Study Team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med. 1997;337:725-733.
  3. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Annals Intern Med. 2001;134:761-776.
  4. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Annals Intern Med. 2001;134:978-996.
  5. Hammer SM. Increasing choices for HIV therapy. New Engl J Med. 2002;346:2022-2023.
  6. Hammer SM, Vaida F, Bennett KK, et al (for the AIDS Clinical Trials Group 398 Study Team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169–180.
  7. Hammer SM, Bassett R, Squires KE, et al. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1–infected persons with virological failure receiving indinavir." Antivir Ther. 2003;8:507-518.
  8. Acosta EP, Wu H, Hammer SM, et al. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;37:1358-1366.
  9. Sobieszczyk ME, Coakley EP, Wilkin TJ, Hammer SM. Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Top HIV Med. 2004;12:9-29.
  10. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843. (Prior recommendations published in 2004, 2002, 2000, 1998, 1997, 1996)